Clinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials

Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer

(2015) Karen L. Reckamp et al.   CANCER

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Patients With Biomarker-Selected Non–Small-Cell Lung Cancer

(2015) Martin J. Edelman et al.   JOURNAL OF CLINICAL ONCOLOGY

The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials

(2014) Haili Qian et al.   BMC CANCER

Efficacy and Safety Profile of Celecoxib for Treating Advanced Cancers: A Meta-analysis of 11 Randomized Clinical Trials

(2014) Jian Chen et al.   CLINICAL THERAPEUTICS

Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials

(2014) Wei-Xiang Qi et al.   CURRENT MEDICAL RESEARCH AND OPINION

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced Non–Small-Cell Lung Cancer

(2014) Barbara J. Gitlitz et al.   Journal of Thoracic Oncology

Cox-2 in non-small cell lung cancer: A meta-analysis

(2013) Hao Jiang et al.   CLINICA CHIMICA ACTA

Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy

(2012) Sverre Sörenson et al.   EUROPEAN JOURNAL OF CANCER

Targeting apoptosis pathways by Celecoxib in cancer

(2011) Verena Jendrossek   CANCER LETTERS

Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group

(2011) Andrea Koch et al.   EUROPEAN JOURNAL OF CANCER

Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression As a Biomarker for Patients With Advanced Non–Small-Cell Lung Cancer: The NVALT-4 Study

(2011) Harry J.M. Groen et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non-Small Cell Lung Cancer

(2009) R. Mutter et al.   CLINICAL CANCER RESEARCH

Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer

(2009) Bjørn H. Grønberg et al.   JOURNAL OF CLINICAL ONCOLOGY

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2009) Alessandro Liberati et al.   PLOS MEDICINE

Cyclooxygenase-2 Expression Is an Independent Predictor of Poor Prognosis in Colon Cancer

(2008) S. Ogino et al.   CLINICAL CANCER RESEARCH

Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy—Cancer and Leukemia Group B Trial 30203

(2008) Martin J. Edelman et al.   JOURNAL OF CLINICAL ONCOLOGY